Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
C 1.34 1.52% 0.02
DRRX closed up 1.52 percent on Friday, November 1, 2024, on 89 percent of normal volume.
Earnings due: Nov 11
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Fell Below 20 DMA Bearish 1.52%
NR7 Range Contraction 1.52%
Down 3 Days in a Row Weakness 1.52%
Fell Below 50 DMA Bearish -0.74%
Upper Bollinger Band Walk Strength -0.74%
Gapped Down Weakness -0.74%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 21 hours ago
Down 1% about 21 hours ago
Gap Up Closed 1 day ago
20 DMA Resistance 1 day ago
20 DMA Support 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DURECT Corporation Description

DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pain Organic Compounds Chemical Compounds FDA Cardiovascular Disease Euphoriants Polymers Opioids Chronic Pain Schizophrenia Drug Delivery Central Nervous System Disorders Nervous System Disorders Chronic Disease Ethers Attention Deficit Hyperactivity Disorder Morphinans Hyperactivity Disorder Pharmaceutical And Medical Device Adhd Drug Delivery Technology Excipients Phenols Bupivacaine Hydrocodone Transdermal Fentanyl Oxycodone Excipient Hydromorphone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder

Is DRRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.7697
52 Week Low 0.4703
Average Volume 57,490
200-Day Moving Average 1.23
50-Day Moving Average 1.39
20-Day Moving Average 1.35
10-Day Moving Average 1.41
Average True Range 0.10
RSI (14) 47.09
ADX 15.85
+DI 20.49
-DI 18.62
Chandelier Exit (Long, 3 ATRs) 1.26
Chandelier Exit (Short, 3 ATRs) 1.48
Upper Bollinger Bands 1.49
Lower Bollinger Band 1.21
Percent B (%b) 0.46
BandWidth 20.79
MACD Line 0.01
MACD Signal Line 0.01
MACD Histogram -0.0002
Fundamentals Value
Market Cap 39.97 Million
Num Shares 29.8 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.88
Price-to-Sales 2.50
Price-to-Book 1.58
PEG Ratio -0.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.46
Resistance 3 (R3) 1.46 1.42 1.44
Resistance 2 (R2) 1.42 1.39 1.42 1.43
Resistance 1 (R1) 1.38 1.37 1.40 1.38 1.43
Pivot Point 1.34 1.34 1.35 1.34 1.34
Support 1 (S1) 1.30 1.31 1.32 1.30 1.25
Support 2 (S2) 1.26 1.29 1.26 1.25
Support 3 (S3) 1.22 1.26 1.24
Support 4 (S4) 1.22